Heart Views

EDITORIAL
Year
: 2002  |  Volume : 3  |  Issue : 2  |  Page : 4-

Percutaneous valve implantation: Milestone or Millstone?


Roxane McKay 
 Department of Cardiology and Cardiovascular Surgery, Hamad Medical Corporation, Qatar

Correspondence Address:
Roxane McKay
Consultant Congenital Heart Surgeon, Hamad Medical Corporation,P.O. Box 3050, Doha
Qatar




How to cite this article:
McKay R. Percutaneous valve implantation: Milestone or Millstone?.Heart Views 2002;3:4-4


How to cite this URL:
McKay R. Percutaneous valve implantation: Milestone or Millstone?. Heart Views [serial online] 2002 [cited 2022 Dec 5 ];3:4-4
Available from: https://www.heartviews.org/text.asp?2002/3/2/4/64467


Full Text

Valvar lesions remain a challenging niche in the management of congenitally malformed hearts. In addition to prosthetic characteristics, issues of somatic growth, life-style preferences, long-term ventricular function, and multiple reoperations may impact upon both the timing and outcome of any intervention. Moreover, in contrast to acquired pathology on the left side of the heart, the indications for and benefits of pulmonary valve replacement have been less clearly defined and more difficult to balance against small but definite risks of resternotomy and cardiopulmonary bypass.

In this issue of Heart Views, Boudjemline and Bonhoeffer summarize their experience with percutaneous implantation of a gluteraldehyde preserved bovine venous valve into the right ventricular outflow tract of nine patients. By any standard, this is a remarkable technical achievement. Implantation was performed successfully and without significant complications in all nine cases where it was attempted, and, at a mean follow-up of eleven months, all valves were either completely competent or had trivial leakage on color Doppler echocardiography. Not only was improved right ventricular function achieved through reduction of the regurgitant volume overload, but also the early effects of valve implantation were isolated from those of surgical trauma and cardiopulmonary bypass, thus possibly demonstrating that a competent valve may be of potentially more benefit than previously recognized.

Although presently applicable to only a small subset of patients, if, as the authors propose, it shows long-term durability and can be adapted to other types pathology, this procedure could have considerable impact upon surgical management of the right ventricular outflow in a number of congenital heart malformations. For example, percutaneous valve implantation might be planned routinely to subsequently compensate transannular outflow patching in repair of Fallots tetralogy, which is frequently necessary [1] and presently perceived to be a disadvantage of operation in early infancy. Or, the surgeon might endeavor to use a larger, valved extracardiac conduit in the correction of pulmonary atresia or truncus arteriosus, with the knowledge that a second valve could later be implanted within the graft. Given that pulmonary regurgitation rarely if ever requires emergency correction, another possibility could be the incorporation of tissue engineering, such that a "scaffold" was placed percutaneously into the right ventricular outflow tract, and the patients own cells then grew into it over a period of time to form a viable, competent valve.

The authors also describe their experimental work in preparation for aortic valve replacement and suggest that valves might be inserted into the atrioventricular positions or the Fontan circulation using percutaneous techniques as well. While these feats may well become possible in patients during the next few years, (and the authors enthusiasm for application of their technology is understandable), one wonders if this should not, perhaps, be tempered by the known results of similar procedures which have been done surgically for many years. In the higher-pressure systemic circulation, durability of the prosthesis assumes increasing importance.

While improvements have been made in the preparation of gluteraldehyde-preserved tissues [2] , evidence that this will significantly prolong their longevity in young patients is still awaited. And, as the authors themselves note, such limitations are shared equally by surgical and percutaneous approaches. In the case of Fontan pathways, neither homograft valves nor the native pulmonary valve have been demonstrated to function effectively long-term. [3] Not withstanding occasional reports of improvement in protein-losing enteropathy after valve implantation, [4] current trends are to minimize rather than incorporate so-called "energy sinks" in this particular circulation. [5] Indiscriminate insertion of valve tissue merely

because it can be done percutaneously could potentially become the reinvention of a wheel that has already turned rather poorly. Finally, one cannot help but note that a new word - "valvulation"- has been invented to describe this procedure! In the future, will we need to qualify whether the patient has undergone open, surgical "valvulation" or percutaneous, interventional "valvulation"? Or should we not, without recourse to Greek and Latin justification, just continue to use the accurately descriptive terms of "valve implantation?" Boudjemline, Bonhoeffer, and their colleagues [6] are certainly to be congratulated for an important addition to the armaments of interventional cardiology. As the frontiers of this subspeciality approach those of cardiac surgery, however, it becomes increasingly important that patients benefit from the history, traditions, and innovations of both.

References

1Walsh EP, Rockenmacher S, Keane JF, Hougen TJ, Locke JE, Castaneda AR. Late results in patients with tetralogy of Fallot repaired during infancy. Circulation 1988;77:1062-7.
2Mayne AS, Christie GW, Smaill BH, Hunter PJ, Barratt- Boyes BG. An assessment of the mechanical properties of leaflets from four second-generation porcine bioprostheses with biaxial testing techniques.J Thorac Cardiovasc Surg 1989;98:170-80.
3Ishikawa T, Neutze JM, Brandt PW, Barratt-Boyes BG. Hemodynamics following the Kreutzer procedure for tricuspid atresia in patients under two years of age. J Thorac Cardiovasc Surg 1984;88:373-9.
4Crupi G, Locatelli G, Tiraboschi R. Villani M, De Tommasi M, Parenzan L. Protein-losing enteropathy after Fontan operation for tricuspid atresia (imperforate tricuspid valve). Thorac Cardiovasc Surg 1980;28:359-63.
5Mighavacca F, de Leval MR, Dubini G, Pietrabissa R, Fumero R. Computational fluid dynamic simulations of cavopulmonary connections with an extracardiac lateral conduit. Med Eng Phys 1999;21:187-93.
6Bonhoeffer P, Boudjemline Y, Qureshi SA, Le Bidois J, Iserin L, Acar P, Merckx J, Kachaner J, Sidi D. Percutaneous insertion of the pulmonary valve. J Am Coll Cardiol 2002;39:1664-9.